Today’s Short Interest: Celgene Corporation (NASDAQ:CELG) Stock Is Shorted More

November 29, 2016 - By Marguerite Chambers   ·   0 Comments

Today's Short Interest: Celgene Corporation (NASDAQ:CELG) Stock Is Shorted More

The stock of Celgene Corporation (NASDAQ:CELG) registered an increase of 3.02% in short interest. CELG’s total short interest was 9.26M shares in November as published by FINRA. Its up 3.02% from 8.99M shares, reported previously. With 5.05M shares average volume, it will take short sellers 2 days to cover their CELG’s short positions. The short interest to Celgene Corporation’s float is 1.2%. The stock closed at $120.3 during the last session. It is down 11.85% since April 26, 2016 and is uptrending. It has outperformed by 6.60% the S&P500.

Celgene Corporation is a biopharmaceutical company. The company has a market cap of $92.67 billion. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 45.59 P/E ratio. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin).

Insitutional Activity: The institutional sentiment increased to 1.11 in Q2 2016. Its up 0.12, from 0.99 in 2016Q1. The ratio improved, as 70 funds sold all Celgene Corporation shares owned while 411 reduced positions. 60 funds bought stakes while 418 increased positions. They now own 587.22 million shares or 5.24% less from 619.66 million shares in 2016Q1.
The Texas-based Kanaly Trust has invested 0.02% in Celgene Corporation (NASDAQ:CELG). Sectoral Asset, a Quebec – Canada-based fund reported 416,704 shares. Pub Employees Retirement Association Of Colorado holds 164,328 shares or 0.13% of its portfolio. Dynamic Capital Mgmt Ltd has 0.3% invested in the company for 25,716 shares. Segment Wealth Limited Liability Co holds 0.1% or 2,500 shares in its portfolio. Mai has 0.03% invested in the company for 3,743 shares. The Massachusetts-based Jp Marvel Inv Ltd Liability Com has invested 2.08% in Celgene Corporation (NASDAQ:CELG). Art Advsrs Ltd Liability Co accumulated 0.52% or 104,954 shares. Security National Trust reported 1,640 shares or 0.06% of all its holdings. Advisor Ptnrs Ltd holds 0.35% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 10,215 shares. Bessemer Group Incorporated Incorporated accumulated 0.01% or 16,892 shares. Davis holds 4.49% or 64,117 shares in its portfolio. The Sweden-based Amf Pensionsforsakring has invested 1.22% in Celgene Corporation (NASDAQ:CELG). First Manhattan owns 147,830 shares or 0.09% of their US portfolio. Dupont Cap Mngmt has 163,008 shares for 0.36% of their US portfolio.

Insider Transactions: Since July 28, 2016, the stock had 0 insider buys, and 10 selling transactions for $46.59 million net activity. The insider Friedman Michael A sold 18,600 shares worth $2.16M. Shares for $11.00M were sold by HUGIN ROBERT J. CASEY MICHAEL D sold $4.92M worth of Celgene Corporation (NASDAQ:CELG) on Monday, August 22. LOUGHLIN JAMES J had sold 27,500 shares worth $3.14 million. $1.64 million worth of Celgene Corporation (NASDAQ:CELG) was sold by MARIO ERNEST. Shares for $1.03M were sold by KAPLAN GILLA on Thursday, September 15. BARKER RICHARD W sold $2.22 million worth of stock or 20,000 shares.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Out of 21 analysts covering Celgene Corporation (NASDAQ:CELG), 17 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 81% are positive. Celgene Corporation has been the topic of 38 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Suntrust Robinson maintained Celgene Corporation (NASDAQ:CELG) rating on Friday, April 29. Suntrust Robinson has “Buy” rating and $147 price target. The rating was initiated by Leerink Swann with “Market Perform” on Friday, February 5. Standpoint Research initiated Celgene Corporation (NASDAQ:CELG) on Thursday, January 14 with “Buy” rating. Cowen & Co maintained it with “Outperform” rating and $150 target price in Wednesday, August 12 report. The rating was maintained by Wells Fargo on Friday, December 4 with “Outperform”. Jefferies maintained the shares of CELG in a report on Wednesday, October 5 with “Buy” rating. The firm has “Outperform” rating by RBC Capital Markets given on Friday, January 29. The firm earned “Buy” rating on Friday, July 15 by Stifel Nicolaus. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, April 19 report. The rating was initiated by Suntrust Robinson on Thursday, January 7 with “Buy”.

CELG Company Profile

Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Fool.com which released: “Better Buy: Celgene Corporation vs. Merck & Co.” on November 25, 2016, also Fool.com with their article: “Better Buy: Biogen Inc. vs. Celgene Corporation” published on November 15, 2016, Fool.com published: “3 Compelling Reasons to Buy Celgene Corporation Stock Right Now” on November 17, 2016. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Businesswire.com and their article: “Celgene Corporation to Webcast an Analyst and Investor Event from the American …” published on November 21, 2016 as well as Fool.com‘s news article titled: “Better Buy: Celgene Corporation vs. Bristol-Myers Squibb” with publication date: November 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>